Belgian pediatric CR network launched
The Belgian Pediatric Society (SBP), the Federal Medicines Agency (AFMPS) and pharma.be, the latter representing local and international research-based drugmakers in Belgium, have combined to form the Belgian Pediatric Clinical Research Network in order to stimulate the development of therapies aimed for children. The pharma.be, in a statement, noted that it is contributing an initial subsidy of 100,000 euros ($128,190) towards start-up costs for the new body.
The BPCRN is intended by its founders to "significantly improve the quality, efficacy and safety of medicines for children, in the image of what already exists in Germany, France and the Netherlands." It is based on the requirements of the European Commission's Regulation on Medicinal Products for Pediatric Use, which became effective on January 1, 2008. Among the regulation's provisions are the creation of a European pediatric medicines committee and the implementation of pediatric investigation plans (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze